CMPS
COMPASS Pathways Plc−$3.15 (27.19%) At close $8.42 · Today
☾After Hours +$0.31 (3.70%) Nov 2, 4:45 PM ET
About CMPS
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
Company
- Headquarters
- Chesire, X0
- Employees
- 156 (2026)
- Listed
- Sep 18, 2020
- Exchange
- Nasdaq
- Website
- compasspathways.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #127 of 430
- P/B #28 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.26T-0.46%
- JNJJohnson & Johnson$651.3B-0.97%
- ABBVAbbVie Inc$510.4B-2.05%
- MRKMerck & Co Inc$366.0B-0.78%
- NVSNovartis AG$304.9B+0.42%
Financial summary
Related companies
About
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
From company filings and market data · Not investment advice
Price data
52W range and average volume from daily bars (unadjusted, last 252 sessions).
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.